All News
Unmasking Lupus Pregnancy: Adherence and Drug Monitoring Dilemmas
Risk of poor pregnancy outcomes in lupus patients continues to remain high, especially in the setting of high disease activity. Preliminary data from a lupus pregnancy LEGACY cohort presented at EULAR 2023 raise concern.
Read Article
With the single cell RNA sequencing analysis being my more affordable (relatively) and widely used! Science is moving forward. Highlights in basic science and translational data #EULAR2023 @RheumNow https://t.co/sS7xLeNyLW
Bella Mehta bella_mehta ( View Tweet)
#EULAR2023 #LB0005 Can we improve trial design of Bcell depletion in #SLE? Feasibility RCT of RTX in organ specific MSK showed: a)feasible to use ultrasound & clinical as endpoints, b)new tool LAMDA is responsive, c)potential worsening before later improvement with RTX @RheumNow https://t.co/kGDZ6EqLtq
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Promising new therapies in SLE
Dr. Yuz Yusof ( @Yuz6Yusof ) weighs in.
The pharmacology treatment in SLE is a rapidly expanding field of research that provides excitement and optimism to both the patients and the clinicians.
https://t.co/0G6EMYp2mb https://t.co/Yc31sR4fRE
Links:
Dr. John Cush RheumNow ( View Tweet)
Tune it at 1pm EST for RheumNow's daily #EULAR23 recaps. You can find us live on Twitter, YouTube and LinkedIn. https://t.co/t531csjXo8
Dr. John Cush RheumNow ( View Tweet)
#EULAR2023 #OP0290 Heterogeneity in #SLE is not only disease features but think of ANCESTRY. Data from BILAG-BR registry showed worse outcomes in people of Black and South Asian treated with either Rituximab or Belimumab (adjusted for deprivation index) @RheumNow https://t.co/bcdu9RIFSx
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Predictors of first hospitalizations due to disease activity and infections in #lupus 1341 pts from multicenter latin american cohort. 33% with atleast one hospitalization, and 3/4th due to disease activity.
@rheumnow #EULAR2023 abt#POS0169 https://t.co/vbJU4220is
Bella Mehta bella_mehta ( View Tweet)
Evaluation of diagnostic performance of ACR 1997, SLICC 2012 and EULAR /ACR diagnostic crieteria in childhood onset #SLE - SLICC highest sensitivity early in the disease,
ACR1997 has the highest specificity both at diagnosis ans over time.
@RheumNow #EULAR2023 abst#POS0136
Bella Mehta bella_mehta ( View Tweet)
#EULAR2023 #POS1124 My newly diagnosed patients & their carers often expressed heightened anxiety with poor quality web info about #SLE. Thank you @LupusEurope for this wonderful effort đź‘Ź. Available in most European languages too @RheumNow https://t.co/cr5Ls117xM
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2023 #POS1128 Promising new therapy on the block for #lupus nephritis. A single arm Phase 2a study showed Zetomipozomib, selective immunoproteosome-i + MMF showed about 2/3 pts met =>50% reduction in uPCR at WK24. No safety signal including low IgG or infection @RheumNow https://t.co/0A8cCW5GVV
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2023 #OP0226 DORIS remission in #SLE is a goal but may be slight tricky to achieve. Multicentre cohort study showed attainment of LLDAS protected against subsequent Flare and Damage @RheumNow https://t.co/MIypIDW6aE
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
We know HCQ adherence is poor in both RA and SLE
>50% in this BC 🇨🇦 cohort
All despite being such an important medicine
What’s super interesting are the trajectories of adherence - and we’d like to understand more about what motivates each group
OP0222 #EULAR2023 @RheumNow https://t.co/rbx1l9T36C
David Liew drdavidliew ( View Tweet)
Antimalarial adherence in RA and SLE showed 4 patterns of adherence over time, with 53% drop off in 1 year, with higher adherence with age, SLE and socioeconomic class, Hoque MR, Abst#0222 #EULAR2023 @RheumNow https://t.co/Bld5kWVQxE
Dr. Antoni Chan synovialjoints ( View Tweet)
Fatigue in SLE remains a challenge!
Online digital tool - LEAF - Lupus Expert System for Assessment of Fatigue - assement of fatigue PROMs in 1250pts - 80% reported fatigue, 93% found tool helpful @rheumnow #EULAR2023
Need more tools to assess and manage fatigue!
abst#OP0230
Bella Mehta bella_mehta ( View Tweet)
#EULAR2023 POS1190-HPR Besides genetic influence, what do patients with #SLE think re: cause of the disease? A survey in N=290 in Sweden showed stress, hormones & infection as the next top 3 causes. Those reported the first two had different education & perceived health @RheumNow https://t.co/GhyCyp7EWU
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Watch: Baricitinib in Lupus Nephritis
Dr. Peter Nash reports on abstract OP0053 presented at EULAR 2023 in Milan, Italy.
https://t.co/U9sIkCs7dX https://t.co/MgmVHo7wZo
Links:
Dr. John Cush RheumNow ( View Tweet)
Lots of early pipeline data in lupus at #EULAR2023 mainly in the supplement!
AFIMETORAN dual TLR7/8 ANTAGONIST in lupus mice! Maybe steroid sparing! Abst#AB0132
@RheumNow
Bella Mehta bella_mehta ( View Tweet)
#lupus Phase 1 data #EULAR2023 humanised, afucosyl IgG1 antibody against CXCR5 – receptor on B cells and bonafide T follicular helper(Tfh) and circulating T follicular helper-like(cTfh) cells – Potent, tolerated and caused depletion of cells in SLE and RA.
Abst#AB0511 @rheumnow
Bella Mehta bella_mehta ( View Tweet)
bone complications #SLE – imp to maintain vitamin D levels!
Osteonecrosis of the femoral head (ONFH) and Avascular osteonecrosis (AVN) – total 86 pts – 60 had both ONFN and AVN.
ONFN often b/l more morbidity, raynauds and low vit D compared to AVN
Abst#AB0566#EULAR2023 @rheumnow
Bella Mehta bella_mehta ( View Tweet)
Overview of treatment strategies in #Lupus #EULAR2023 #Rheumtwitter https://t.co/zL1nEDajsb
Christian Ammitzbøll RheumTweeter ( View Tweet)
